BPC-157: the version I wish someone had shown me in week 1
BPC-157: the version I wish someone had shown me in week 1. Numbers below. Ask me the boring questions, they are the useful ones.
Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read.
Why identity, not purity, is the test to buy here.
This is a short peptide with a published sequence. Synthesis is not difficult, which means the market is wide and the analytical question shifts. A high area-percent figure tells you the sample is homogeneous; it does not tell you the homogeneous material is the sequence you ordered.
Mass spectrometry, with the theoretical mass alongside the measured one, converts a purity claim into an identity claim. It costs a little more and it answers the question that actually matters. Ask for it, and ask suppliers whether they can provide it before you order — the answers are informative in themselves.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.
Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.
Right, and regulatory status has genuinely moved in several jurisdictions. Answers from three years ago may be wrong now.
What jurisdiction are you asking about? The answer has changed in several.
most of the claims here trace to the same handful of rodent papers
preclinical enthusiasm is not clinical evidence
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
regulatory status varies by jurisdiction and it has moved recently
pentadecapeptide, fifteen residues, and the sequence is public
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.
identity testing matters more here than purity does
Agreed. Identity is the question here. A short peptide can be synthesised by almost anyone and the sequence is what you are actually buying.
identity, quantity, stability — three separate questions
identity testing matters more here than purity does
This is the point that should be at the top of every thread here. Identity first.
Small fix — fifteen residues, not seventeen.
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.
stability in solution is the practical question nobody asks
short peptides are cheap, which cuts both ways
read the actual papers, they are more modest than the summaries
a fifteen-residue peptide is easy to make and easy to make badly
Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.
- 1The published literature is overwhelmingly preclinical, largely in rodent…12 comments in this branch · started by u/ilias_kaufmann